Author Affiliations: Department of Child and Adolescent Mental Health, University Hospital of Erlangen, Erlangen (Drs Heinrich, Studer, Moll, and Kratz), and Heckscher-Klinikum, Munich (Dr Heinrich), Germany.
In the light of personalized medicine, future studies should not only address the question of whether one therapy is generally superior than another but also investigate which therapy may work best in a particular patient. In this respect, the article by Schulz and colleagues,1 in which the neural mechanisms of methylphenidate and atomoxetine during response inhibition were studied in children with attention-deficit/hyperactivity disorder (ADHD) by functional magnetic resonance imaging, appears to be highly relevant, particularly since neural changes are considered in relation to clinical improvements.
Heinrich H, Studer P, Moll GH, Kratz O. Methylphenidate vs Atomoxetine: Personalized Medicine in Attention- Deficit/Hyperactivity Disorder. JAMA Psychiatry. 2013;70(5):545. doi:10.1001/jamapsychiatry.2013.760